Zepbound, Mounjaro shortages drag on

Four more solutions of Zepbound and Mounjaro are in limited supply, and the shortages have prolonged, the FDA said April 17. 

On April 3, the agency's drug shortage database listed two solutions of Zepbound (tirzepatide), a weight loss drug, and four solutions of Mounjaro (tirzepatide), a Type 2 diabetes medication. At the time, Eli Lilly said it expected those shortages to end in April. 

Two weeks later, the database now lists 10 solutions in low supply throughout the first half of 2024. Only two presentations are available at normal supply levels: Mounjaro injection, 2.5 milligram per 0.5 milliliters, and Zepbound injection, 2.5 milligram per 0.5 milliliters. 

The extended supply issues were published the same day Eli Lilly announced promising results on the drugs as potential obstructive sleep apnea treatments. The drugmaker said it plans to apply for expanded drug labels by mid-2024.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars